The Pulmonary Pharmacology Group is interested in studying methods to improve the lives of cystic fibrosis patients through personalized medicine.

Cystic Fibrosis is an autosomal recessive condition caused by a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. When the CFTR protein is dysfunctional the cells cannot move chloride and water effectively. This causes a buildup of mucus in the lungs leading to infections, inflammation, respiratory failure, and other complications. In the pancreas, the buildup of mucus prevents the release of digestive enzymes that help the body absorb food and key nutrients, resulting in malnutrition and poor growth. In the liver, the thick mucus can block the bile duct, causing liver disease. In men and women, CF can affect their ability to have children. There have been many advances in the treatment of cystic fibrosis using CFTR modulators. These medications have resulted in a large percentage of the CF population living much longer and having a better quality of life. While these advances are amazing, we continue to have room for improvement of care. Now that CF patients live longer, their comorbidities have become more prominent, and there are still CF patients that these new medications do not help them.